Company · Healthtech & Bio

ALLOX

allox.bio ↗ ·Barcelona ·Pre-seed

ALLOX is a Barcelona-based techbio spin-off from the Centre for Genomic Regulation (CRG) that combines high-throughput experimental genetics, AI, and biophysical energy models to systematically discover allosteric drug-target sites on proteins previously considered 'undruggable.' Founded in 2023, it aims to accelerate therapeutics for diseases such as cancer by mapping how mutations affect protein regulation. It closed an undisclosed pre-seed round in 2023 backed by Asabys Partners, Artá Capital, and Spain's CDTI innovation agency.

Founded

2023

Founders

News

Rounds

Investors

SectorsBiotechnology, Drug Discovery, Computational Biology, AI/Machine Learning Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 27 Jul 2026

Founders

André Faure

CTO & Co-founder

Ben Lehner

Chief Scientific Advisor & Co-founder

Júlia Domingo

CEO & Co-founder

Pablo Baeza Centurión

Chief Discovery Officer & Co-founder

Global models 5

Xaira Therapeutics

United States · xaira.com ↗

Uses generative AI and large-scale experimental data to design proteins/therapeutics, the same 'AI + biology platform for drug discovery' model as ALLOX but at massive scale.

$1.1BComparable

Insitro

United States · insitro.com ↗

Combines machine learning with high-throughput functional genomics to identify drug targets, closely mirroring ALLOX's genetics+AI target-discovery approach.

$743MComparable

Isomorphic Labs

United Kingdom · www.isomorphiclabs.com ↗

AI-first drug discovery company modeling protein structure/function to find novel drug targets, similar computational-biology-driven discovery model.

$600MComparable

Recursion Pharmaceuticals

United States · www.recursion.com ↗

Built a large-scale AI/ML platform mapping biology to find drug targets and candidates, the same data-driven target-discovery thesis as ALLOX.

$500M+Comparable

Exscientia

United Kingdom · www.exscientia.ai ↗

AI-designed drug discovery platform pairing computational models with experimental biology, directly comparable to ALLOX's platform approach (now merged into Recursion).

$500M+Comparable

Investors 3

Artá Capital

Investor Spain

Funding rounds 2

Seed

CDTI Innovación announced an equity investment in Allox (Allostery Exploration Technologies) alongside Asabys Partners; the amount was not d…

2024-09-12

Pre-seed

ALLOX, a techbio spin-off of the Centre for Genomic Regulation that designs drugs targeting allosteric sites on 'undruggable' proteins, anno…

2023-11-30

News & media 4

Published	Article
2025-05-22	ALLOX, the startup exploring allosterism to revolutionize drug development ↗ AseBio
2025-05-07	ALLOX, the startup using allostery to revolutionize drug development ↗ Parc Científic de Barcelona
2024-07-03	Júlia Domingo, CEO of ALLOX (CRG): "We will generate innovative therapies for currently untreatable diseases" ↗ El·lipse (PRBB)
2023-11-30	ALLO X, a new Centre for Genomic Regulation spin-off, is launched with the support of Asabys ↗ Centre for Genomic Regulation (CRG)